ILF3 and hepatocellular carcinoma: Lefamulin overcomes drug resistance of HCC by targeting ILF3 and blocking GCN5 and CBP‐mediated acetylation of ILF3, which subsequently inhibits MRPL12 transcription and mediates mitochondrial homeostasis.